Company Filing History:
Years Active: 2020
Title: The Innovations of Cyril Berthet
Introduction
Cyril Berthet is a notable inventor based in Dijon, France. He has made significant contributions to the field of medical imaging, particularly in the development of radiolabeled compounds for cancer diagnosis.
Latest Patents
Cyril Berthet holds a patent for a "Radiolabeled macrocyclic EGFR inhibitor." This invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which are suitable as positron emission tomography (PET) tracers for imaging epidermal growth factor receptors (EGFR). The patent outlines their use in in vivo diagnosis, preclinical and clinical tumor imaging, patient stratification based on the mutational status of EGFR, and assessing tumor response to therapeutic treatments. The invention is particularly relevant to various cancers influenced by deregulated EGFR, including non-small cell lung cancer, pancreatic cancer, and breast cancer, among others.
Career Highlights
Cyril Berthet is associated with Oncodesign SA, a company focused on innovative solutions in the field of oncology. His work has contributed to advancements in cancer diagnostics and treatment strategies.
Collaborations
Cyril has collaborated with notable colleagues such as Jan Marie Cyriel Jozef Hoflack and Petra Marcella Françoise Blom, enhancing the research and development efforts in his field.
Conclusion
Cyril Berthet's innovative work in the development of radiolabeled compounds for cancer imaging represents a significant advancement in medical technology. His contributions continue to impact the field of oncology and improve patient outcomes.